EP0537232A1 - Vaccin recombine contre l'avipoxvirose du pigeon - Google Patents

Vaccin recombine contre l'avipoxvirose du pigeon

Info

Publication number
EP0537232A1
EP0537232A1 EP91912297A EP91912297A EP0537232A1 EP 0537232 A1 EP0537232 A1 EP 0537232A1 EP 91912297 A EP91912297 A EP 91912297A EP 91912297 A EP91912297 A EP 91912297A EP 0537232 A1 EP0537232 A1 EP 0537232A1
Authority
EP
European Patent Office
Prior art keywords
virus
pigeon pox
pox virus
gene
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91912297A
Other languages
German (de)
English (en)
Other versions
EP0537232A4 (en
Inventor
Guy Meulemans
Carine Letellier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0537232A1 publication Critical patent/EP0537232A1/fr
Publication of EP0537232A4 publication Critical patent/EP0537232A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the field of treatments for avian Newcastle Disease. More particularly, the present invention relates to recombinant viral vaccine treatment of Newcastle Disease.
  • Newcastle disease is the most important viral disease of poultry. Newcastle disease is a highly contagious and destructive infection which attacks chickens, turkeys, pigeons and numerous species of wild and captive birds. Mortality due to Newcastle disease depends both on the immune status of the birds and on the virulence of the Newcastle disease virus. Mortality due to Newcastle disease can reach 100%. Chickens appear to the be most susceptible species.
  • Newcastle disease virus the avian paramyxovirus type 1 is the etiological agent of Newcastle disease.
  • Newcastle disease virus strains are classified in three pathotypes: velogenic, mesogenic and lentogenic.
  • Velogenic and mesogenic Newcastle disease virus strains are the pathogenic strains whilst lentogenic strains cause no mortality in birds of any age and are currently used as live vaccine strains against Newcastle disease virus.
  • live vaccine strains include Hitchner, LaSota and Ulster strains.
  • SUBSTITUTE SHEET Currently used live vaccines, however, have several disadvantages including thermal sensitivity, residual pathogenicity, possible reversion to virulence and neutralization by homologous antibodies. In addition, disease eradication programs are hindered by the inability to distinguish vaccinated from infected chickens on a serological basis.
  • Newcastle disease virus F glycoprotein expressed from a recombinant Vaccinia virus vector protected chickens against live-virus challenge.
  • the Vaccinia virus vaccine could protect chicks against infection with Newcastle disease virus, the researchers were unable to show seroconversion against the Vaccinia component of the recombinant virus in the inoculated chicks. Inability of Vaccinia virus to grow in chickens has been reported. Although adaptation of Vaccinia virus to the chicken is possible, nevertheless, the use of Vaccinia recombinant viruses in chickens is not reasonable since Vaccinia infects humans and its use as a vaccine could be hazardous for human health.
  • SUBSTITUTE SHEET related avian pox virus modified by the insertion of foreign DNA into a non-essential region of the fowl pox virus.
  • EPO publication number 0 314 569 discloses recombinant fowl pox virus wherein the fowl pox virus is modified in a non-coding region between genes to contain DNA coding for a heterologous protein.
  • fowl pox virus has a more restricted range than Vaccinia virus, and does not infect humans, it nonetheless is generally more virulent in some avian species, particularly turkeys and chickens, two economically important species.
  • the present invention provides recombinant pigeon pox virus synthetically modified by the presence, in a non-essential region of the pigeon pox virus genome, of DNA not naturally occurring in pigeon pox virus.
  • pigeon pox virus is modified within the thymidine kinase gene to contain DNA not naturally occurring in pigeon pox virus.
  • a preferred DNA sequence for insertion within the thymidine kinase gene is DNA coding for the Newcastle disease virus F protein.
  • Figure 1 shows the nucleotide sequence of the insert of clone 11.14, in the mRNA sense, that codes for Newcastle disease F gene.
  • the present invention provides recombinant pigeon pox virus synthetically modified by the presence, in a non-essential region of the pigeon pox virus genome, of DNA not naturally occurring in pigeon pox virus.
  • the recombinant virus of the invention it will be possible to vaccinate avian species simultaneously against at least two different diseases.
  • the recombinant virus of the invention will provide protection against both pigeon pox virus and a second virus, such as Newcastle disease virus, or other organism.
  • the recombinant pigeon pox virus contains the Newcastle disease virus F gene.
  • Recombinant pigeon pox virus containing Newcastle disease F gene will differentiate Newcastle disease virus antibodies produced in response to the recombinant pigeon pox virus from antibodies due to infection since birds inoculated with the recombinant virus will not produce antibodies to all antigenic epitopes of Newcastle disease virus unless they are challenged by the virus itself.
  • pigeon pox virus is less pathogenic for chickens and turkeys. Thus the chances of adverse reactions to the virus vector are reduced with the use of pigeon pox virus as the vector virus.
  • SUBSTITUTE SHEET recombinant pigeon pox virus is useful for inoculation of species capable of being infected with pigeon pox virus including chickens, turkeys and pigeons, as well as species capable of being infected with the organism whose characteristic DNA has been inserted into the pigeon pox virus.
  • the recombinant pigeon pox virus of the invention may be administered as a pharmaceutical preparation according to established protocols for the administration of vaccines to birds, such as those disclosed in Tripathy and Cunningham Avian Pox in Diseases of Poultry, eighth edition, Iowa State University Press, Ames, Iowa, USA, 1984, Chapter 23 Avian Pox, including the wing web method and the feather follicle method, or according to the methods employed when administering commercially available pigeon pox or fowl pox vaccines.
  • the recombinant virus of the invention is administered in combination with a pharmaceutically acceptable carrier or diluent, such as water, saline, or other buffer.
  • the pharmaceutical preparation may also contain additional ingredients such as an adjuvant or stabilizer.
  • the particular route of administration, the age of birds at administration and the dosage will depend on such factors as the species, age and weight of the bird.
  • the route of administration, the age of the birds, and the dosage of recombinant virus, vaccine or pharmaceutical preparation may also vary according to the type of DNA not naturally occurring in pigeon pox virus expressed by the recombinant virus.
  • recombinant pigeon pox virus expressing the F gene of Newcastle disease virus it has been found that vaccination with a virus produced in chicken embryo skin cells having a viral titer of ⁇ o*5-3 TCID50 per milliliter was effective to protect SPF chickens when challenged with Newcastle disease virus strain Italian.
  • UBSTITUTE SHEET Commercially available pigeon pox virus useful as a vaccine or research strains of pigeon pox virus are suitable for use as the viral vector in the invention.
  • Pigeon pox virus used in a preferred embodiment of the invention was obtained from Rit SA, Genval, Belgium, and has registration number 6100.
  • the recombinant pigeon pox virus of the invention is produced by synthetically inserting into the genome of the virus DNA not normally occurring in pigeon pox virus.
  • the DNA not normally occurring in pigeon pox virus i.e. foreign DNA or heterologous DNA is inserted into a non-essential portion of the genome of the virus, i.e. within the thymidine kinase gene.
  • the foreign DNA may be inserted into intergenic regions of the pigeon pox virus.
  • Foreign DNA coding for a desired gene product that will be inserted to the pigeon pox virus vector is selected according to the type of organism it is desired to protect against, or other purpose.
  • the DNA not normally occurring in pigeon pox virus is characteristic of, or codes for a protein against which neutralizing antibodies can be formed in the inoculated host, particularly proteins involved with the fusion of a virus to a host cell.
  • a preferred DNA sequence is the Newcastle disease virus F gene. Recombinant pigeon pox virus containing this gene will protect inoculated birds against infection by both pigeon pox and Newcastle disease viruses.
  • DNA coding for antigenic proteins from other viruses or other organisms may be substituted for the Newcastle disease F gene to provide protection against the respective virus or other organism.
  • the foreign DNA is preferably inserted into the pigeon pox vector operatively linked with transcription control elements to ensure proper transcription of the foreign gene. In a preferred embodiment of the invention, the foreign DNA is operatively linked with
  • the Vaccinia pll K promoter is derived from the Vaccinia virus gene that encodes a late 11,000-dalton polypeptide (UK) , see Bertholet, C.R. e__ .al. (1985) Proc. Natl. Acad. Sci. USA £2: 2096-2100; and Coupar, B.E.H. fit al * (1986) Eur. J. Immunol. 1£: 1479-1487, the disclosures of which are hereby incorporated as if fully set forth herein.
  • Other transcription control elements that are compatible with pigeon pox virus, such as pigeon pox virus promoters may also be used.
  • plasmid vectors may be constructed that contain defined Vaccinia virus promoters, restriction sites for the insertion of foreign coding sequences, and flanking sequences of the pigeon pox TK gene.
  • the Newcastle disease F gene is operatively linked with Vaccinia promoter upstream
  • the Newcastle disease F gene and Vaccinia promoter are linked upstream and downstream with flanking sequences of the pigeon pox thymidine kinase gene (thymidine kinase gene sequence, promoter, Newcastle disease F gene, thymidine kinase gene sequence, respectively) .
  • the plasmid DNA is then transfected into cells infected with pigeon pox virus, wild-type or modified, where homologous recombination occurs. Transfection may be done by standard methods such as calcium phosphate coprecipitation or electroporation. The host cells are then tested for the presence of recombinant virus expressing the foreign gene. Insertion of the foreign DNA into the thymidine kinase gene renders recombinant virus TK-.
  • TK ⁇ recombinants may be isolated by a plaque assay in the presence of bromodeoxyuridine (BUdR) a nucleoside analogous to thymidine, but highly mutagenic and poisonous to organisms such as a cell or virus when present in DNA contained therein.
  • BdR bromodeoxyuridine
  • Other methods of selecting recombinant virus may be found in Boyle and Coupar (1988) Virus Research M: 343-356.
  • SUBSTITUTE SHEET Although the recombinant virus of the invention has been cultured in chicken cells, cells of other species capable of infection with pigeon pox virus are also suitable for culture of the recombinant virus.
  • two recombinant viruses expressing the F gene have been isolated.
  • PPV/F 22 recombinant virus expressing the F gene was derived from high passaged pigeon pox virus.
  • the viral strain developed as vector virus is the pigeon pox virus available from Rit SA (Genval, Belgium) registration number 6100 which is for vaccinating chickens against fowl pox by the wing web procedure.
  • All cell cultures used for the adaptation and multiplication of pigeon pox virus were primary cultures made from SPF chicken embryos (Lohman, Cuxhaven, Germany) .
  • Primary chicken embryo skin cells were obtained by trypsinization of whole 12-day old embryos and grown in Opti-MEM (Gibco) containing 10% fetal calf serum. For maintenance of the cells, fetal calf serum was omitted from the medium.
  • Primary chicken embryo fibroblast cells were prepared by trypsinization of minced 9-to 10-day old chicken embryos and grown in Opti-MEM. For maintenance of the cells, fetal calf serum was omitted from the medium.
  • hepatocyte cells were prepared from the liver of 14 day old embryos in Opti-MEM containing 10% fetal calf serum as growth medium. Maintenance medium was ELY (Gibco) supplemented with 12% fetal calf serum. All cell cultures were incubated at 38.5° C in the presence of 5% carbon dioxide.
  • SUBSTITUTE SHEET primary chicken hepatocyte cells After 6 days incubation, the progeny virus was recovered by three cycles of freezing and thawing and was further adapted to cell cultures by successive passages in chicken hepatocyte cells, chicken embryo skin cells and chicken embryo fibroblast cells. Two different adapted viruses were obtained: low passaged pigeon pox virus and high passaged pigeon pox virus. Low passaged pigeon pox virus was prepared by two passages in chicken hepatocyte cells, followed by two passages in chicken embryo skin cells, followed by two passages in chicken embryo fibroblast cells (6 passages in total) .
  • the last passage (6th passage) was titrated in chicken embryo fibroblast cells and had a titer of 10 6 - 20 TCID50 per milliliter.
  • High passaged cells were prepared by subjecting low passaged pigeon pox virus to an additional 25 passages in chicken embryo fibroblasts (31 passages in total) .
  • High passaged pigeon pox virus was titrated in chicken embryo fibroblasts and had a titer of 10 7 - 00 TCID 50 . Determinat.ion of EID 50 and TCID 50
  • EID50 is the dose of virus that will infect fifty per cent of the test group of embryos.
  • TCID5 Q is the dose of virus that will infect 50% of the test group of cell cultures.
  • the EID50 and TCID50 may be calculated according to standard methods, such as the method in Villegas and Purchase, "Titration of Biological Suspensions" in Isolation and identification __£ uzla n Pathogens r second edition, The
  • Newcastle disease F gene as disclosed in copending, commonly assigned U.S. patent application serial number 07/441,182, filed November 22, 1989, the disclosures of which are hereby incorporated by reference as if fully set forth herein, was used in constructing the recombinant pigeon pox virus. The method for cloning this gene is set forth below.
  • BHK-21 cells were infected at a multiplicity of 5 to 10 PFU (Plaque Forming Units) /cell. After an absorption period of thirty minutes, the cells were incubated at 37° C in Eagle minimal essential medium (MEM) .
  • PFU Plaque Forming Units
  • actinomycin D was added at a final concentration of 2 ug/ l, and four hours later, the cells were washed twice with TNE buffer (0.01M Tris, pH 8.3, 0.15M NaCl, O.OOIM EDTA) and lysed in TNE-SDS buffer (0.01M Tris pH 8.3, 0.15M NaCl, O.OOIM EDTA, 0.5% SDS) containing 400 ug/ml of proteinase K. After addition of one volume of phenol: chloroform; isoamyl alcohol (25:24:1) the DNA was broken in a mixer and the mixture extracted twice with phenol:chloroform;isoamyl alcohol (1 volume) .
  • nucleic acids were pelleted and dissolved in elution buffer (0.1M Tris pH 7.5, O.OOIM EDTA, 0.5% SDS) and the mixture was made 2M in LiCl and incubated at 4° C for 12 hours. After centrifugation, the pellet was dissolved in 2ml of hybridization buffer (0.1M Tris, pH 7.5,
  • the poly(A) + -mRNAs were tested for stimulation of protein synthesis in rabbit reticulocyte lysates (Palham, H.R.B. et al. Eur. J. Biochem. £1:247-256 (1976)); the synthesized viral proteins were detected by immunoprecipitation with specific anti-NDV antibodies, as described by Le Long et al. (1986) J. Virol, hi: 1198-1202.
  • the cDNAs were then inserted into the PstI site of oligo(dG)-tailed pBR322 plasmid DNA by (dG) n - (dC) n hybridization, and the ligation mixture was used to transform E. coli strain MM294 (2 ⁇ dR17, i.e., r ⁇ ⁇ m + ⁇ ) to tetracycline resistance.
  • DNA SEQUENCE ANALYSIS DNA sequence was determined by the chemical method of Maxam & Gilbert and by the Sanger dideoxy sequencing method.
  • the recombinant cDNA clone (11.14) was chosen for DNA sequence analysis because it possesses the largest insert among the clones containing F-specific sequences. More than 94% of the sequence of both strands of the F protein coding region was determined.
  • the entire nucleotide sequence of the insert of clone 11.14, in the mRNA sense, is shown in Figure 1. It contains 1764 base pairs excluding poly(A) tract and G- C tails. There is only a single long open reading frame, starting at the ATG (nucleotides 68-70) , and ending with an core termination codon (nucleotides 1646-1648) . This end codon is followed by four additional in-frame terminators.
  • SUBSTITUTE SHEET The coding region encodes a protein of 526 a ino acids (M r )
  • F2 probably extends from residue 19 to residue 98 and consists of 890 amino acids (M r 8,304 without any carbohydrate composition) ;
  • F- ⁇ is a polypeptide of 423 amino acids (residues
  • F contains four potential glycoslyation sites: one on F2 and three on F- ⁇ .
  • High passaged pigeon pox virus was purified by sucrose gradient ultracentrifugation and viral DNA was extracted using the phenol/chloroform procedure. The DNA was recovered by ethanol precipitation and digested by EcoR I before ligation into lambda gt 10 vector (Promega, Madison, Wisconsin) . Clones containing the pigeon pox virus thymidine kinase gene were identified by hybridization using a 32p oligonucleotide made on the sequence of the thymidine kinase gene of fowl pox virus published by Boyle and Coupar (1988) Virus Research 1Q.: 343-356.
  • the sequence of the oligonucleotide probe used is 5'GAT AAA TAC ATA GCC GTG TGT AGG 3'.
  • a positive clone was multiplied and the insert was digested with restriction enzymes to give a Cla I - BamH I fragment of 2,540 base pairs containing the entire pigeon pox virus thymidine kinase gene. This fragment was cloned into the Ace I - Sma I site of plasmid p SP65 (Promega, Madison, Wisconsin) to create plasmid p SP65 TK.
  • the EcoR I site of p SP65 TK was then deleted using the Klenow fragment of DNA polymerase I, and an EcoR I site was introduced into the unique Nco I site of the pigeon pox virus thymidine kinase gene.
  • the F gene was obtained from pBR322 Clone (11.14) by enzymatic digestion using Bam HI and F sp I restriction enzymes. The Bam HI end of the F gene was made blunt using the Klenow fragment of DNA poly erase I. The blunt ended F gene was then cloned into the PvuII site of plasmid YEP36 (Butt et al. (1984) Proc. Natl. Acad. Sci USA £1: 3332-3336), which was modified by deletion of the galactokinase coding gene to create plasmid YEP36/F. An EcoRI fragment containing the Newcastle disease virus F gene was obtained by enzymatic digestion of plasmid YEP36/F, which was then ligated into the Eco RI site of pSP64 (Promega, Madison, Wisconsin) .
  • the F gene from Newcastle disease virus was removed from plasmid p SP 64 by EcoR I digestion.
  • the ECO RI fragment represents most of the F coding sequence (1721 nucleotides) and still contains an ATG codon, the second one in the F sequence.
  • the p 7.5 - p 11 K and F fragments were ligated together into the unique EcoR I site (ERI) of p SP 65 TK.
  • the recombinant plasmid was characterized by restriction analysis for the presence of the F sequence in the correct orientation, downstream of the p 11 K promoter.
  • the sequence at the junction of the promoter and the Newcastle disease F gene was determined and was as follows:
  • SUBSTITUTE SHEET Transaction and isolation of recombinant pigeon pox virus Primary chicken embryo fibroblast cells were infected either with low passaged pigeon pox virus or high passaged pigeon pox virus at 0.05 PFU/cell and transfected with 5 micrograms of plasmid using Lipofectin Reagent (Bethesda Research Laboratories, Gaithersburg, Maryland) according to the manufacturer's instructions. Recombination between plasmid and viral genome generated thymidine kinase negative pigeon pox virus recombinants which were isolated by plaque assay in primary chicken embryo skin cells in the presence of bromodeoxyuridine (BUdR) at a concentration of 25 micrograms per milliliter.
  • BdR bromodeoxyuridine
  • PPV/F 22 recombinant virus expressing the F gene was derived from high passaged pigeon pox virus.
  • PPV/F 26 recombinant virus expressing the F gene was derived from low passaged pigeon pox virus.
  • Stability of the recombinant viruses was assessed by making four successive multiplications in chicken embryo skin cells of the fourth clonage of PPV/F 22 and PPV/F 26 and testing the progeny virus by immunofluorescence and radio immunoprecipitation studies using a polyclonal antiserum to Newcastle disease virus or the F protein according to the methods of LeLong et al. supra, and Espion et al. supra. Both tests were positive. Immunization Studies
  • the fourth chicken embryo skin cell passage of PPV/F 26 was used for vaccinating SPF chickens.
  • the viral titer of the virus was 10 ⁇ * 3 TCID 50 per milliliter.
  • Eighteen six week old sPF chickens were vaccinated by the feather follicle method.
  • Challenge was performed 20 days later by intramuscular injection of 10 ⁇ EID 50 of the velogenic Newcastle disease virus strain Italian.
  • Ten four week old SPF chickens were included as challenge controls. All the birds were observed for one month after challenge. All control chickens died within 6 days after challenge. Only one of the vaccinated chickens died during the total observation period.
  • Serological testing was performed by ELISA and he agglutinin inhibition reaction according to the method in Meulemans et al.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Poxvirus recombiné du pigeon modifié synthétiquement par la présence, dans une région non essentielle du génome du poxvirus du pigeon, d'ADN non naturel dans le poxvirus du pigeon. Dans un mode de réalisation préféré de l'invention, on modifie le poxvirus du pigeon à l'aide d'au moins une partie du gène F du virus de la maladie de Newcastle, par insertion du gène F dans le locus de thymidinekinase dans le génome du poxvirus du pigeon.
EP19910912297 1990-07-02 1991-07-01 Recombinant pigeon pox virus vaccine Withdrawn EP0537232A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54747090A 1990-07-02 1990-07-02
US547470 1990-07-02

Publications (2)

Publication Number Publication Date
EP0537232A1 true EP0537232A1 (fr) 1993-04-21
EP0537232A4 EP0537232A4 (en) 1993-06-30

Family

ID=24184753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910912297 Withdrawn EP0537232A4 (en) 1990-07-02 1991-07-01 Recombinant pigeon pox virus vaccine

Country Status (6)

Country Link
EP (1) EP0537232A4 (fr)
JP (1) JPH05508540A (fr)
KR (1) KR930701588A (fr)
AU (1) AU8213391A (fr)
CA (1) CA2084064A1 (fr)
WO (1) WO1992000372A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025666A1 (fr) * 1992-06-16 1993-12-23 Commonwealth Scientific And Industrial Research Organisation Virus entomophiles recombinants
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
US6241991B1 (en) * 1998-03-05 2001-06-05 Akzo Nobel N.V. Aviadenovirus
CN107630036A (zh) * 2017-10-16 2018-01-26 佛山科学技术学院 一种番鸭细小病毒vp1基因重组鸽痘病毒转移载体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308220A1 (fr) * 1987-09-16 1989-03-22 Nippon Zeon Co., Ltd. Avipoxvirus recombinant
EP0404576A2 (fr) * 1989-06-22 1990-12-27 Nippon Zeon Co., Ltd. Virus d'avipox recombinant
EP0419666A1 (fr) * 1988-12-29 1991-04-03 Nippon Zeon Co., Ltd. Promoteur, plasmide le contenant, et avipoxvirus de recombinaison

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429965A (en) * 1966-08-01 1969-02-25 Sterling Drug Inc Avian pox virus vaccine and process of preparing same
WO1988002022A1 (fr) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Virus de la variole recombinant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308220A1 (fr) * 1987-09-16 1989-03-22 Nippon Zeon Co., Ltd. Avipoxvirus recombinant
EP0419666A1 (fr) * 1988-12-29 1991-04-03 Nippon Zeon Co., Ltd. Promoteur, plasmide le contenant, et avipoxvirus de recombinaison
EP0404576A2 (fr) * 1989-06-22 1990-12-27 Nippon Zeon Co., Ltd. Virus d'avipox recombinant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF VIROLOGY vol. 118, no. 1-2, 1991, WIEN, AUSTRIA pages 43 - 56 LETELLIER, C. ET AL. 'Construction of a pigeonpox virus recombinant: expresiion of the Newcastle disease virus (NDV9 fusion glycoprotein and protection of chickens against NDV challenge' *
See also references of WO9200372A1 *

Also Published As

Publication number Publication date
CA2084064A1 (fr) 1992-01-03
JPH05508540A (ja) 1993-12-02
KR930701588A (ko) 1993-06-12
EP0537232A4 (en) 1993-06-30
AU8213391A (en) 1992-01-23
WO1992000372A1 (fr) 1992-01-09

Similar Documents

Publication Publication Date Title
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
US5093258A (en) Recombinant fowlpox virus and recombination vector
EP0353851B1 (fr) Régions non essentielles du virus du fowlpox
US5182210A (en) Fowlpox virus promoters
KR102070217B1 (ko) 다가 재조합 조류 헤르페스 바이러스 및 조류 종을 면역화하기 위한 백신
US5187087A (en) Recominbant herpesvirus of turkeys and live vector vaccines derived thereof
JP3411307B2 (ja) 組み換えアビポックスウイルス、該ウイルスを感染させた細胞の培養及び該ウイルスから誘導されるワクチン
CA2166371A1 (fr) Vaccin recombinant vivant pour oiseaux, a base de virus herpetique aviaire, actif notamment contre la maladie de gumboro
US6913751B2 (en) Recombinant avian herpesvirus useful in vaccine production
EP0868522B1 (fr) Virus de recombinaison combine de la variole et de la peritonite infectieuse du chat, compositions le contenant et leurs procedes d'obtention et d'utilisation
JP2007254489A (ja) Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物
US20100008948A1 (en) Recombinant herpesvirus useful in vaccine production
EP0831899B1 (fr) Compositions a base de poxvirus-calicivirus recombinants et leurs utilisations
WO1994019014A1 (fr) Avipox virus recombine s-fpv-043 et ses utilisations
WO1996039177A9 (fr) Compositions a base de poxvirus-calicivirus de recombinaison [virus de la maladie hemorragique du lapin (rhdv)] et leurs utilisations
Smith et al. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences
EP0537232A1 (fr) Vaccin recombine contre l'avipoxvirose du pigeon
WO2007115385A2 (fr) Vecteur plasmidique de transfert et virus canarypox recombinant
US5374558A (en) Fowlpox virus promoter
EP0606452A1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
US5874280A (en) Vector vaccines of bovine herpesvirus I
AU769221B2 (en) Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
Moss Vaccinia virus vectors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched

Effective date: 19930511

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950201